Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L.
Honig LS, et al. Among authors: li d.
Alzheimers Res Ther. 2024 May 10;16(1):105. doi: 10.1186/s13195-024-01441-8.
Alzheimers Res Ther. 2024.
PMID: 38730496